8-K: Recursion Reports Promising Clinical Data and Outlines Strategic Growth Following Exscientia Merger

Recursion announces positive clinical trial results, partnership milestones, and financial updates for Q4 and fiscal year 2024, highlighting its advancements as a leading TechBio company after merging with Exscientia.

Summary

• Recursion reported business updates and financial results for Q4 and fiscal year 2024, ended December 31, 2024.
• The company highlighted promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and encouraging trends in efficacy for REC-994 in cerebral cavernous malformations.
• Three new clinical studies were initiated across oncology, rare disease, and recurrent C. diff infection with REC-1245, REC-4881, and REC-3964.
• Milestones were achieved for partners, including Roche, Genentech, and Sanofi, resulting in $45 million in aggregate cash inflows.
• The business combination with Exscientia was completed, solidifying Recursion's position as a leading TechBio company.
• Cash, cash equivalents, and restricted cash were $603.0 million as of December 31, 2024, with an expected cash runway into 2027.
• Total revenue for 2024 was $58.8 million, compared to $44.6 million in 2023.
• Pro forma revenue for 2024, including Exscientia as if the merger occurred on January 1, 2023, was $82.6 million.
• Research and development expenses were $314.4 million for 2024, compared to $241.2 million in 2023.
• Net loss for 2024 was $463.7 million, compared to $328.1 million in 2023.
• The company is on track to achieve at least $100 million in synergies from the Exscientia transaction, with the majority expected in 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting promising clinical data, strategic partnerships, and a strong cash position. While acknowledging increased expenses and net losses, the emphasis on future synergies and a catalyst-rich 2025 suggests confidence in the company's growth trajectory.

Positives

• Promising early clinical data for REC-617 and REC-994.
• Advancement of multiple pipeline programs into clinical trials.
• Successful achievement of partnership milestones with Roche, Genentech, and Sanofi.
• Completion of the Exscientia merger, enhancing the company's TechBio capabilities.
• Strong cash position providing a runway into 2027.
• Expected synergies of at least $100 million from the Exscientia merger.
• Development of BioHive-2, a powerful supercomputer for biopharma research.
• Integration of Exscientia's Centaur platform into Recursion OS, improving molecule design.

Negatives

• Decrease in Q4 2024 revenue compared to Q4 2023 due to the timing of projects from the Roche and Genentech collaboration.
• Increased research and development expenses in 2024 due to platform expansion and personnel costs.
• Increased general and administrative expenses in 2024 due to salaries, transaction costs, and the inclusion of Exscientia's results.
• Net loss increased in 2024 compared to 2023, driven by higher operating costs.
• Net cash used in operating activities increased in 2024 compared to 2023.

Risks

• Challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs.
• Ability to leverage and enhance the drug discovery platform.
• Ability to obtain financing for development activities and other corporate purposes.
• Success of collaboration activities.
• Ability to obtain regulatory approval of, and ultimately commercialize, drug candidates.
• Ability to obtain, maintain, and enforce intellectual property protections.
• Cyberattacks or other disruptions to technology systems.
• Ability to attract, motivate, and retain key employees and manage growth.
• Inflation and other macroeconomic issues.

Future Outlook

Recursion expects to achieve at least $100 million in synergies from the Exscientia transaction, with the majority of the run rate amount achieved in 2025, and anticipates a catalyst-rich 2025 with multiple clinical and partnership milestones.

Management Comments

• With a portfolio of 10 clinical and preclinical programs, including both potential first-in-class and best-in-class therapies, we are driving towards faster and more effective drug development, said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion.
• These advances position us at the forefront of the next generation of medicine, where the impact will be measured not just in scientific breakthroughs through the power of our platform, but in real-world patient outcomes at scale.

Industry Context

The announcement highlights Recursion's strategic positioning in the TechBio sector, leveraging AI and machine learning to accelerate drug discovery and development. The merger with Exscientia and partnerships with major pharmaceutical companies like Roche, Genentech, and Sanofi underscore the growing trend of collaboration between technology and biotechnology companies to drive innovation in healthcare.

Comparison to Industry Standards

• Recursion's approach to drug discovery, leveraging AI and machine learning, aligns with industry trends towards data-driven drug development, similar to companies like Schrödinger and Relay Therapeutics.
• The company's focus on generating large-scale biological datasets and building foundation models like Phenom-2 and MolGPS mirrors efforts by other TechBio companies to create predictive models for drug discovery.
• The reported cash runway into 2027 provides Recursion with financial stability comparable to other well-funded biotech companies, allowing for sustained investment in research and development.
• The expected synergies of $100 million from the Exscientia merger demonstrate a commitment to operational efficiency, a key focus for companies in the competitive biotech landscape.
• Recursion's partnerships with Roche, Genentech, and Sanofi are similar to strategic collaborations seen across the industry, where biotech companies leverage the expertise and resources of larger pharmaceutical firms to advance their programs.

Stakeholder Impact

• Shareholders: Potential for increased value through pipeline advancement and strategic partnerships.
• Employees: Opportunities for growth and development within a leading TechBio company.
• Patients: Potential for new and improved treatments for various diseases.
• Partners: Collaborative opportunities to leverage Recursion's platform and expertise.
• Creditors: Financial stability supported by a strong cash position.

Next Steps

• Initiation of combination studies for REC-617 in 1H25.
• Phase 1 first patient dosed for REC-3565 in B-cell malignancies in 1H25.
• Phase 1 first patient dosed for REC-4539 in SCLC in 1H25.
• Phase 1b/2 safety and early efficacy data for REC-4881 in FAP in 1H25.
• PFS6 futility analysis for REC-2282 in NF2 in 1H25.
• Program update for REC-994 in 2H 2025.
• Additional Phase 1 data from ELUCIDATE for REC-617 in 2H25.
• Phase 2 update for REC-3964 in 1Q26.
• Phase 1 update in dose-escalation for REC-1245 in 1H26.
• Comprehensive update on synergies from the Exscientia transaction in May 2025.

Key Dates